Biogaran is said to be valued at over EUR 800m in BC Partners deal

Biogaran is said to be valued at over EUR 800m in BC Partners deal

July 2, 2025 - BC Partners and Servier have entered into exclusive negotiations for the acquisition of Biogaran, a leading generic drug company in France. The potential transaction, valued at over EUR 800 million, aims to strengthen Biogaran's position in the French market and drive its expansion into new high-potential market segments.

Biogaran, founded by Servier over 25 years ago, has established itself as a key player in the generic pharmaceutical industry. With a wide range of medicines, including antibiotics, antidiabetics, and anticancer drugs, Biogaran contributes significantly to cost savings in the French healthcare system. The company is now poised to benefit from the strategic expertise and operational insights of BC Partners, a leading European investment firm with extensive experience in the French market.

BC Partners, with nearly four decades of investment experience in France, plans to help accelerate Biogaran's growth while continuing to champion essential, affordable healthcare. The firm's deep pharmaceutical sector expertise and long-term capital make it a trusted partner for local entrepreneurs and management teams.

Cédric Dubourdieu, Partner and Head of France at BC Partners, stated, "Biogaran is a recognized leader in the French healthcare sector, with a rich history and compelling opportunity for continued growth. We look forward to helping drive the business forward, in partnership with management, while respecting the vital role Biogaran plays within France’s healthcare landscape and French society more broadly."

Mark Hersee, Partner and Co-head of Healthcare at BC Partners, commented, "Biogaran is a pioneer in generic drugs, a market we know incredibly well, and one where we have developed tried-and-tested playbooks for growth over many years. Our experience in this space, from successful investments in generic pharmaceutical leaders such as Pharmathen and Synthon, means we are well positioned to help the company identify opportunities and boost its full potential."

The proposed transaction remains subject to the finalization of definitive agreements, the appropriate employee representative processes, and the usual regulatory approvals. Servier was advised by Lazard and Dentons, while BC Partners was advised by Rothschild & Cie, Kirkland & Ellis, Gide Loyrette Nouel, and Eight Advisory.

References:
[1] https://www.bcpartners.com/news/servier-and-bc-partners-enter-exclusive-negotiations-for-the-sale-of-biogaran/